Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3e9d77ff72f5282325b4e142dfa5b4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_203f7fb905111dbb86feae8f5ab278c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6983bfd800a91940f75444b0206cb71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_feccd3e88d69dc577d9755c6afbc5cdc |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-345 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
filingDate |
1998-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dc980b2cf31b125c1509b352bd68319 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9da8cf3186ff7a9fa76771e6f8a188a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87dd293a5aabe65025874bee6d2a4afd |
publicationDate |
1999-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-9910486-A2 |
titleOfInvention |
Mdm2-specific antisense oligonucleotides |
abstract |
The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6184212-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7186556-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1165145-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6599741-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1165145-A1 |
priorityDate |
1997-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |